ELK4 has been recognized as a promising target for treating multiple malignancies (33, 34), as inhibiting its expression or activity can constrain the proliferation, migration, and immune evasion of tumor cells, while enhancing sensitivity to chemotherapy and immunotherapy. This evidence concerns the gene ELK4 and neoplasm.